Navigation Links
Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
Date:5/2/2013

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4® bi-functional chelator technology and has extended the collaboration to include additional chelator families.  These technologies are currently being developed by Algeta to conjugate thorium-227 to tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs).Lumiphore's Lumi4® technology is based on a unique class of bi-functional metal chelators1 that forms a cage structure surrounding and tightly binding thorium-227, which can then be covalently attached to a range of tumor-targeting molecules, such as monoclonal antibodies, to create cancer therapeutics.  These bi-functional chelators provide a critical component enabling payload delivery for radio-therapeutic agents.  Algeta originally signed an option/license agreement with Lumiphore around this technology in 2010 and subsequently extended it to enable further evaluation to be conducted.  This stage of evaluation has now been completed successfully.

In parallel with this license agreement, Algeta has also been granted a license by Lumiphore covering a second class of bi-functional chelators that bind strongly to thorium-227, with the option of including a further selection of compounds within that license, if future exploratory work confirms their promise.  Under the agreements, Algeta has the future potential to develop in vivo companion diagnostics for radio-imaging.

"Lumiphore's goal is to bring the benefits of bi-functional metal-chelation technology, through a variety of synthetic designs, to therapeutic markets that use targeted radiopharmaceuticals to treat cancer by the tumoricidal action of the radionuclide micro-irradiation.  The ability to chelate radioactive metal isotopes (radiotracers) and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond , President and CEO of Lumiphore.  "Our technology also offers another therapeutic modality for those using antibody-drug conjugates," explained Steve Blose , Lumiphore's Chief Business Officer. He further explained that pharmaceutical companies using therapeutic antibodies could incorporate Lumiphore's technology to develop site-directed in vivo radiodiagnostics to diagnose and monitor therapeutic efficacy through radio-imaging.

Thomas Ramdahl, Algeta's Chief Technology Officer, said: "Algeta is assembling a broad portfolio of proprietary technologies (including bi-functional chelators, linkers and tumor-targeting molecules), intellectual property and expertise as a platform for generating Target Thorium Conjugates, or TTCs.  The addition of the Lumiphore technologies to the portfolio through this license and further option agreements will ensure that we have access to the best bi-functional chelators for thorium-227 as we seek to create a pipeline of TTCs designed to address multiple high-value opportunities in targeted cancer therapy."

About Lumiphore, Inc.Based in Richmond, California, Lumiphore, Inc., a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide and chelation technology for use in high-value imaging and therapeutic applications which are commercialized through market-specific alliances with corporate partners.  Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond , a world expert on lanthanide and actinide chemistry.  For more information please visit www.lumiphore.com. Lumi4® is a registered mark of Lumiphore, Inc.

About AlgetaAlgeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.  The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA).  For more information please visit www.algeta.com.

MEDIA CONTACTSFor Lumiphore, Inc.Kenneth N. Raymond, Ph.D.

President and Chairman

Tel./FAX: +510-232-8455

kraymond@lumiphore.comFor Algeta ASAMike Booth / Renate Birkeli

+47 23 00 67 32Communications & Corporate Affairs

ir@algeta.comMedia enquiries:Mark Swallow

+44 207 638 9571Citigate Dewe Rogerson

mark.swallow@citigatedr.co.ukKnut Ekern

+47 22 04 82 00Gambit Hill & Knowlton

knut.ekern@hkstrategies.com Kari Watson

+1 781 235 3060MacDougall Biomedical Communications

kwatson@macbiocom.com 1 Known as aromatic macrocyclic bi-functional chelators (AMBFs): one end binds the radionuclide/radiotracer (thorium-227) and the other end links to the tumor-targeting molecule.


'/>"/>
SOURCE Lumiphore, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... ... Pot Valet is a leading provider of premium medical-grade cannabis in California. ... soon, every state in the country, the company offers patients safe, legal, and discreet ... , According to Pot Valet, all California patients have the legal right to ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Great Employers , an international competition, were announced today. The awards recognize the ... and suppliers who help to create and drive great places to work. , ...
(Date:8/16/2017)... , ... August 16, 2017 , ... The next Patient ... being accepted. , Students who successfully complete the seven-week long Patient Care Academy ... Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* , ...
(Date:8/16/2017)... Houston, Texas (PRWEB) , ... August 16, 2017 , ... ... Community Credit Union's Stars in the Classroom and will win a visit by a ... in grades K-12 who are at least five years old can visit texanschecking.com/stars to ...
(Date:8/16/2017)... ATLANTA, Georgia (PRWEB) , ... August 16, 2017 ... ... practice in Atlanta, opened their doors. They celebrate 30 years in business this ... to create an up-to-date, inviting, tranquil space to serve their patients. , ...
Breaking Medicine News(10 mins):